Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | DPP4 | P27487 | 4/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046483 | 1.00 | POLB (0.70) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL3431498 | 1.00 | POLB (0.70) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL1712663 | 0.86 | POLB (0.68) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL3427333 | 0.86 | POLB (0.52) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL5046477 | 0.86 | POLB (0.52) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL3431495 | 0.86 | POLB (0.52) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL12156743 | 0.84 | POLB (0.66) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL8573486 | 0.84 | POLB (0.66) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL10272735 | 0.84 | POLB (0.66) | POLBL3MBTL1DPP4DPP8CHRM2 | |
| SCHEMBL3831117 | 0.84 | POLB (0.66) | POLBL3MBTL1DPP4DPP8CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | claimed |
| US-20200308109-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2020-10-01 | — | — | US | disclosed |
| US-20190177271-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2019-06-13 | — | — | US | disclosed |
| US-20150329491-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2345629-B1 | FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | JAPAN TOBACCO INC (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-8871934-B2 | Fluorene compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20130274240-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8343994-B2 | Fluorene compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-2345629-A1 | FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco, Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20100240634-A1 | Fluorene Compound and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | ALLEN DARIN ARTHUR (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030225036-A1 | Non-amidine containing protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1242366-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1140859-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001044172-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000035886-A2 | (HETERO)ARYL-BICYCLIC HETEROARYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329491-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | POLB 1201/4885L3MBTL1 3139/4885DPP4 968/4885 |
| US-20100240634-A1 | Fluorene Compound and Pharmaceutical Use Thereof | FH, PCK2, PC | POLB 1201/4885L3MBTL1 3139/4885DPP4 968/4885 |
| US-20130274240-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | POLB 1201/4885L3MBTL1 3139/4885DPP4 968/4885 |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | TFPI, HABP2, PLAT | POLB 3233/4885L3MBTL1 2707/4885DPP4 389/4885 |
| US-20190177271-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | POLB 1201/4885L3MBTL1 3139/4885DPP4 968/4885 |
| US-20200308109-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | POLB 1201/4885L3MBTL1 3139/4885DPP4 968/4885 |
| US-20030225036-A1 | Non-amidine containing protease inhibitors | TFPI, SERPINE1, HABP2 | POLB 3105/4885L3MBTL1 3163/4885DPP4 381/4885 |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | TFPI, SERPINE1, HABP2 | POLB 3354/4885L3MBTL1 2621/4885DPP4 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.